Cell-free protein synthesis in 2026: overview
Cell-free protein synthesis makes proteins outside living cells, using either biological extracts or reconstituted molecular components. By separating protein production from cell growth, it gives researchers direct control over reaction conditions and supports rapid testing of protein designs. The method is useful for proteins that are difficult to express in cells, but reagent cost, yield consistency and scale-up remain barriers to broader manufacturing.
Recent work is pushing both reaction control and practical deployment. In September 2026, ProSecCO used synthetic operons to map and engineer the Sec translocon, a key route for membrane-protein insertion. Sino Biological’s XPressMAX kit launch in May 2026 targets AI-driven high-throughput screening. Researchers are also testing lower-cost energy inputs, simplified lysates and lyophilized formats. These directions connect cell-free systems to membrane-protein biology, screening and field diagnostics, while industrial adoption remains an open challenge.
- 1More papers, fewer patents: Publications grew 7.4% while patent activity fell 29.4% in the last 12 months versus the previous 12 months.
- 2Control meets access: Simplified reaction recipes and automated workflows aim to make cell-free systems easier to reproduce and scale.
- 3Beyond discovery: Work on lyophilized biosensors and membrane-protein production points toward uses outside conventional laboratory screening.
Top organizations working on cell-free protein synthesis
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to cell-free protein synthesis. Showing 7 of 266 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Thermo Fisher Scientific
Corporate · United States |
Bacterial extracts | NEWS 279 | +71% | Its cell-free protein expression reagents use bacterial extracts to support in vitro protein production for research. |
| 2 | 
Merck Group
Corporate · Germany |
Bacterial extracts | NEWS 191 | +69% | Merck offers cell-free protein expression reagents, including bacterial extract-based systems for in vitro protein production. |
| 3 | 
Northwestern University
Research · United States |
General | PAT 6 · PUB 31 NEWS 2 |
-44% | Researchers use cell-free synthesis to produce and study proteins, including brochosome components, and have patented a platform for producing allergen proteins. |
| 4 | 
Takara Bio
Corporate · Japan |
General | NEWS 48 | -22% | |
| 5 | 
Promega Corporation
Corporate · United States |
General | NEWS 42 | +10% | |
| 6 | 
Stanford University
Research · United States |
Eukaryotic extracts | PUB 26 · NEWS 5 | -6% | Researchers have developed a Pichia pastoris cell-free synthesis platform and study cell-free production of membrane proteins and other targets. |
| 7 | 
Lonza Group
Corporate · Switzerland |
General | NEWS 92 | +88% | |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 6 total
NucleraUnited KingdomIts eProtein Discovery platform uses cell-free expression for rapid protein production and screening. Patents cover CFPS reagent optimization and high-throughput protein-expression screening.
LeniobioGermanyLenioBio develops ALiCE, a plant-based eukaryotic cell-free expression platform for difficult-to-produce proteins. Recent studies have applied it to protein production and noncanonical-amino-acid incorporation.
InsempraGermanyIts patents address cell-free protein expression, including optimized reaction media and linear DNA templates intended to improve production efficiency.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 228 total
- Northwestern UniversityUnited StatesResearchers use cell-free synthesis to produce and study proteins, including brochosome components, and have patented a platform for producing allergen proteins.
- Stanford UniversityUnited StatesResearchers have developed a Pichia pastoris cell-free synthesis platform and study cell-free production of membrane proteins and other targets.
Imperial College LondonUnited KingdomResearchers are developing yeast-based cell-free protein synthesis systems, including Pichia pastoris and Kluyveromyces lactis platforms, and studying their production economics.- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where cell-free protein synthesis innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 266 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Bacterial extracts | Bacterial lysates offer accessible, fast protein production, but may not provide the post-translational modifications required by some targets. | 220 |
Northwestern University, Nuclera, Thermo Fisher Scientific |
| Eukaryotic extracts | Eukaryotic lysates support more complex folding and modifications, with greater preparation demands and potential cost or consistency trade-offs. | 483 |
Insightace Analytic, Dickinson, Researchmoz |
| Reconstituted systems | Purified components provide greater control over reaction chemistry, but assembly and reagent costs can limit access and scale. | 69 |
University of Florida, California Institute of Technology, University of Edinburgh |
| Continuous reaction formats | Continuous formats replenish substrates and remove by-products during synthesis, but add setup and process-control complexity. | 25 |
Hanyang University, Indrashil University, Massachusetts Institute of Technology |
| Membrane-protein platforms | Membrane-protein platforms add lipid environments or scaffolds to support difficult targets, but require specialized reaction conditions. | 88 |
Tsinghua University, Universidad de Guanajuato, Insightace Analytic |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
Grant activity totals $11,515,898 across 21 grants since 2020, indicating continued support for work in the field.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Aug 2026-- Creative Biogene, a leader in innovative biotechnological solutions, exists to advance innovative life science solutions that drive progress and impact. Creative Biogene aims to become a great company that scripts…Press Release Distribution Service
- May 2026Sino Biological’s gene synthesis and cell-free protein expression workflow has recently been used in a study by Tencent AI for Life Sciences Lab. The study was published in Nature Communications and enabled rapid…Scientist Live
- May 2026Thanks to new technologies like artificial intelligence, scientists are increasingly freed from the constraints of the laboratory. It raises questions about how much humans should outsource to robots. SCOTT DETROW…Technology : NPR
- May 20266 minutes BHV Marais’ inter-union alliance condemns disastrous management of the department store A major development reignited the BHV Marais saga this week. The Canadian company Brookfield plans to build a hotel on…News - FashionNetwork.com United Kingdom
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about cell-free protein synthesis
What companies develop or supply cell-free protein synthesis systems?
Thermo Fisher Scientific, Merck Group, Nuclera, Takara Bio and Promega Corporation are among the companies active in this field. Thermo Fisher Scientific and Merck Group offer bacterial extract-based expression reagents. Nuclera’s eProtein Discovery platform supports rapid protein production and screening, while Takara Bio and Promega Corporation are also represented among active organizations.
Which cell-free protein synthesis startups are active?
Nuclera, Leniobio and Insempra are three startups with distinct cell-free protein synthesis approaches. Nuclera develops eProtein Discovery for protein production and screening; Leniobio’s ALiCE platform uses plant-based eukaryotic extracts; and Insempra’s patents address reaction media and linear DNA templates. Their differing platforms target rapid screening, difficult-to-produce proteins and reaction efficiency.
Which universities and research centers work on cell-free protein synthesis?
Northwestern University, Stanford University and Imperial College London are active research organizations in cell-free protein synthesis. Northwestern University studies protein production and has patented an allergen-protein platform. Stanford University researchers have developed a Pichia pastoris system, while Imperial College London works on yeast-based platforms including Pichia pastoris and Kluyveromyces lactis.
How much grant funding has cell-free protein synthesis received?
The reported total is $11,515,898 across 21 grants since 2020. This is a grant-funding indicator rather than a complete measure of investment in the field. Funding-round totals are also reported, but they should be treated cautiously when assessing cell-free protein synthesis specifically because the listed rounds include broad or unrelated organization-level funding.
Who holds the most cell-free protein synthesis patents?
Kangma Healthcode Shanghai Biotech Co. has the highest listed count, with 10 patents. Nuclera has 8, and Northwestern University has 6. Other listed holders include Chugai Pharmaceutical Co., Ltd. and PeptiDream Inc., with 3 each, and TNO and Nisshin Seifun Group Inc., with 2 each.
Is cell-free protein synthesis patent activity growing?
No: patent activity fell 29.4% in the last 12 months compared with the previous 12 months, with 87 patents in the defined window. By contrast, publications grew 7.4%, reaching 260 in the last year. The difference suggests ongoing research activity alongside a softer recent patent trend; it does not by itself establish a change in commercial adoption.
What are the latest developments in cell-free protein synthesis?
ProSecCO, reported in September 2026, uses synthetic operons to map and engineer the Sec translocon. In May 2026, Sino Biological launched its XPressMAX kit for AI-driven high-throughput screening. Recent research also explores phosphoserine as an energy source, simplified and lower-cost systems, and lyophilized biosensors designed for field use.
What are the main approaches to cell-free protein synthesis?
The main approaches are bacterial extracts, eukaryotic extracts, reconstituted systems, continuous reaction formats and membrane-protein platforms. Bacterial extracts are widely used for accessible protein production; eukaryotic extracts can support more complex protein processing. Reconstituted systems prioritize control, continuous formats sustain reactions, and membrane-protein platforms address the special conditions needed for membrane targets.
What are the applications of cell-free protein synthesis?
The listed applications are therapeutic protein production, protein discovery and engineering, diagnostics and biosensors, vaccine development, and synthetic biology prototyping. Cell-free reactions can speed the production and testing of protein variants, support biosensor development, and help assemble or evaluate biological pathways. Their open reaction format also enables researchers to test designs without maintaining living production cells.